Zura Bio Limited
ZURANASDAQHealthcare● Active
$3.53
+$0.13(+3.82%)
Market Cap$229527586
P/E Ratio—
52W High$7.44
52W Low$1
Zura Bio Limited (ZURA) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ZURA · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$0.22
Est. -$0.17 · -29.4%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▼ Miss EPS
ZURA reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.09
Rev. $41.31B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.09
Rev. Est.$41.31B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 13, 2026 | -$0.20 | — | — | — | — | — |
| ▼ Q2 FY2026 | May 7, 2026 | -$0.17 | -$0.22 | -29.4% | — | — | — |
| ▼ Q1 FY2026 | Mar 19, 2026 | -$0.18 | -$0.49 | -172.2% | — | — | — |
| ▼ Q4 FY2025 | Nov 13, 2025 | -$0.19 | -$0.21 | -10.5% | — | — | — |
| ▲ Q3 FY2025 | Aug 14, 2025 | -$0.19 | -$0.17 | +10.5% | — | — | — |
| ▼ Q2 FY2025 | May 8, 2025 | -$0.17 | -$0.19 | -11.8% | — | — | — |
| ▲ Q1 FY2025 | Mar 25, 2025 | -$0.16 | -$0.08 | +50.0% | $0.00B | — | — |
| ▼ Q4 FY2024 | Nov 7, 2024 | -$0.14 | -$0.26 | -85.7% | — | — | — |
Q3 FY2026
Aug 13, 2026
EPS Actual
—
EPS Est.
-$0.20
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Miss
EPS Actual
-$0.22
EPS Est.
-$0.17
EPS Surpr.
-29.4%
Revenue
—
Q1 FY2026
Mar 19, 2026Miss
EPS Actual
-$0.49
EPS Est.
-$0.18
EPS Surpr.
-172.2%
Revenue
—
Q4 FY2025
Nov 13, 2025Miss
EPS Actual
-$0.21
EPS Est.
-$0.19
EPS Surpr.
-10.5%
Revenue
—
Q3 FY2025
Aug 14, 2025Beat
EPS Actual
-$0.17
EPS Est.
-$0.19
EPS Surpr.
+10.5%
Revenue
—
Q2 FY2025
May 8, 2025Miss
EPS Actual
-$0.19
EPS Est.
-$0.17
EPS Surpr.
-11.8%
Revenue
—
Q1 FY2025
Mar 25, 2025Beat
EPS Actual
-$0.08
EPS Est.
-$0.16
EPS Surpr.
+50.0%
Revenue
$0.00B
Q4 FY2024
Nov 7, 2024Miss
EPS Actual
-$0.26
EPS Est.
-$0.14
EPS Surpr.
-85.7%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.17 | $-0.17 | $-0.17 | 1 |
| Q3 FY2027 | $-0.16 | $-0.16 | $-0.16 | 1 |
| Q2 FY2027 | $-0.15 | $-0.15 | $-0.15 | 1 |
| Q1 FY2027 | $-0.16 | $-0.16 | $-0.16 | 1 |
| Q4 FY2026 | $-0.18 | $-0.18 | $-0.18 | 1 |
| Q3 FY2026 | $-0.21 | $-0.19 | $-0.17 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 7, 2026 | -29.4% | $4.89 | $4.54 | -7.16% |
| ▼ Q1 FY2026 | Mar 19, 2026 | -172.2% | $5.99 | $6.12 | +2.17% |
| ▼ Q4 FY2025 | Nov 13, 2025 | -10.5% | $4.63 | $4.18 | -9.72% |
| ▲ Q3 FY2025 | Aug 14, 2025 | +10.5% | $1.59 | $1.72 | +8.18% |
| ▼ Q2 FY2025 | May 8, 2025 | -11.8% | $1.23 | $1.26 | +2.44% |
| ▲ Q1 FY2025 | Mar 25, 2025 | +50.0% | $1.35 | $1.49 | +10.37% |
| ▼ Q4 FY2024 | Nov 7, 2024 | -85.7% | $4.30 | $4.47 | +3.95% |
| ▼ Q3 FY2024 | Aug 13, 2024 | -30.8% | $3.37 | $3.29 | -2.37% |
Q2 FY2026-7.16%
Report Date
May 7, 2026
EPS Beat/Miss
-29.4%
Price Before
$4.89
Price After
$4.54
Q1 FY2026+2.17%
Report Date
Mar 19, 2026
EPS Beat/Miss
-172.2%
Price Before
$5.99
Price After
$6.12
Q4 FY2025-9.72%
Report Date
Nov 13, 2025
EPS Beat/Miss
-10.5%
Price Before
$4.63
Price After
$4.18
Q3 FY2025+8.18%
Report Date
Aug 14, 2025
EPS Beat/Miss
+10.5%
Price Before
$1.59
Price After
$1.72
Q2 FY2025+2.44%
Report Date
May 8, 2025
EPS Beat/Miss
-11.8%
Price Before
$1.23
Price After
$1.26
Q1 FY2025+10.37%
Report Date
Mar 25, 2025
EPS Beat/Miss
+50.0%
Price Before
$1.35
Price After
$1.49
Q4 FY2024+3.95%
Report Date
Nov 7, 2024
EPS Beat/Miss
-85.7%
Price Before
$4.30
Price After
$4.47
Q3 FY2024-2.37%
Report Date
Aug 13, 2024
EPS Beat/Miss
-30.8%
Price Before
$3.37
Price After
$3.29
Avg Beat Reaction+9.27%
Avg Miss Reaction-1.78%
Beat Rate2 / 8 quarters
Largest Move+10.37% (Q1 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ZURA ends December
Zura Bio Limited (ZURA) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-0.22 — missing the analyst consensus of $-0.17 by -29.4%. The next ZURA earnings date is expected around September 1, 2026.
Each quarter, investors track ZURA earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ZURA revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ZURA's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ZURA earnings · 5 questionsZura Bio Limited's next earnings report is expected around September 1, 2026. ZURA typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ZURA historically reports after market close (AMC).
ZURA earnings datewhen is ZURA earningsZURA next earnings datewhen does ZURA report earningsZURA earnings calendar
▸ Source: FMP · Zura Bio Limited SEC filings · US GAAP · Zura Bio Limited SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026